Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ALE.P02 |
Synonyms | |
Therapy Description |
Limited information is currently available on ALE.P02, a putative antibody-drug conjugate targeting CLDN1 (Feb 2025). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALE.P02 | ALEP02|ALE P02|ALE PO2|ALE.PO2 | Limited information is currently available on ALE.P02, a putative antibody-drug conjugate targeting CLDN1 (Feb 2025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06747585 | Phase Ib/II | ALE.P02 | A Study to Investigate ALE.P02 As Monotherapy in Adult Patients with Selected CLDN1+ Solid Tumors | Recruiting | USA | 1 |